Carnosine
Also known as: β-alanyl-L-histidine · L-carnosine
An endogenous dipeptide (β-alanyl-L-histidine) with distinctive antioxidant, anti-glycation, and metal-chelating properties supporting cellular-protection research applications spanning neuroprotection, cognitive-ageing, and metabolic-cognitive contexts.
Carnosine (β-alanyl-L-histidine) is an endogenous dipeptide with distinctive antioxidant, anti-glycation, and metal-chelating properties available as a dietary supplement.
Evidence tier: C — preclinical / mechanistic evidence only
- Category
- Neuroprotection
- Half-life
- Short plasma half-life owing to serum carnosinase; tissue effects extend beyond exposure
Section 1
Overview
Carnosine is an endogenous dipeptide (β-alanyl-L-histidine) present at high concentrations in mammalian skeletal muscle and CNS tissue. Its distinctive pharmacological properties — antioxidant activity, anti-glycation effects, metal chelation (particularly copper and zinc), and pH buffering — support cellular-protection research applications across multiple tissue systems and research contexts including neuroprotection, cognitive-ageing, and metabolic-cognitive interaction research.
The compound occupies a distinctive research and commercial position: it is widely available as a dietary supplement rather than a research chemical or licensed pharmaceutical, providing sourcing quality and safety framework advantages over most peptides on this reference. This supplement-availability context reflects carnosine's endogenous status and the well-characterised safety profile at physiological-plus doses.
The cognitive-relevance research applications include age-related cognitive decline research (via the antioxidant and anti-glycation mechanisms), Alzheimer's disease research (via the anti-amyloid and metal-chelating mechanisms), and diabetes-associated cognitive dysfunction research (via the anti-glycation mechanism relevant to advanced glycation end-product (AGE) formation). Direct cognitive-endpoint clinical trials in cognitive-decline populations have not been completed at scale.
Section 2
Discovery & History
- Isolated in 1900 by Gulewitsch — one of the earliest identified peptides in biological chemistry, predating most modern peptide research.
- Extensively characterised throughout the 20th century for antioxidant, anti-glycation, and metal-chelating properties.
- Cognitive-relevance research applications emerged in the 1990s-2000s as the anti-glycation mechanism was recognised as relevant to Alzheimer's disease and diabetes-associated cognitive dysfunction research.
- Widely adopted as a dietary supplement in Europe, US, and other markets.
- Continues to be used in research applications across multiple tissue systems and cognitive-relevance research contexts.
Section 3
Mechanism of Action
- 1Antioxidant activity via direct radical-scavenging and quenching of reactive oxygen and nitrogen species — the foundational pharmacological property that underlies multiple downstream research applications.
- 2Anti-glycation effects — inhibition of advanced glycation end-product (AGE) formation, a mechanism directly relevant to diabetes-associated cognitive dysfunction and to age-related protein-modification cognitive-decline contributions.
- 3Metal chelation — copper and zinc binding with distinctive research relevance to Alzheimer's disease (where copper and zinc are implicated in amyloid-beta aggregation) and to broader metal-cognitive interaction research.
- 4pH buffering activity in skeletal muscle and CNS tissue via the imidazole ring pKa near physiological pH — the mechanism-of-action for the muscle-buffering applications and a contribution to cellular-stress-resistance mechanisms.
- 5Anti-amyloid effects reported in Alzheimer's disease preclinical models via multiple mechanisms including direct amyloid-beta binding, metal-chelation-mediated inhibition of amyloid aggregation, and antioxidant protection against amyloid-mediated oxidative damage.
- 6Anti-apoptotic effects in stressed cellular preparations via preservation of mitochondrial function and reduced caspase-3 activation.
- 7Reported effects on cognitive endpoints in aged rodent models, providing behavioural-level evidence for the cognitive-relevance research applications.
Section 4
Researched Benefits
Findings reported in the published preclinical and clinical literature. Effects in research contexts do not constitute claims of therapeutic benefit in humans.
- 1Multiple distinctive pharmacological properties (antioxidant, anti-glycation, metal-chelating, pH-buffering) providing a research-tool niche with broad tissue-system applicability.
- 2Well-characterised anti-glycation activity directly relevant to diabetes-associated cognitive dysfunction and age-related protein-modification cognitive-decline research.
- 3Metal-chelating activity with distinctive Alzheimer's disease research relevance.
- 4Available as dietary supplement providing sourcing quality and safety framework advantages over research chemicals.
- 5Substantial acute and chronic safety database from decades of dietary supplement use.
- 6Endogenous dipeptide status providing a partial safety floor at physiological concentrations.
- 7Small dipeptide chemistry providing practical research handling and stability advantages.
Section 5
Theoretical Dosing & Protocols
| Route | Dosage | Frequency | Duration |
|---|---|---|---|
| Oral (dietary supplement) | 500-2000 mg per day in typical supplement use; higher doses (up to 4000 mg per day) used in some research protocols | Once or twice daily | Chronic supplement use; research protocols continue weeks to months |
Note: Serum carnosinase enzyme activity substantially reduces bioavailable carnosine following oral administration; some research protocols use N-acetyl-carnosine or other analogues to circumvent carnosinase degradation.
Section 6
Administration Routes
- Oral administration — the primary route for supplement use and most research applications.
- Topical administration for skin and eye research applications.
- Intranasal administration explored in some CNS-directed research applications.
- Injection routes used occasionally in research contexts but limited by the short plasma half-life owing to serum carnosinase.
Section 7
Safety Profile
Commonly reported
- · Well-tolerated as dietary supplement across the substantial supplement-use population.
- · Occasional mild gastrointestinal effects at higher doses.
- · No dependence, tolerance, or withdrawal phenomena documented.
- · Endogenous status provides a partial safety floor at physiological concentrations.
Rare / theoretical
- · Rare hypersensitivity reactions.
- · Serum carnosinase deficiency (rare inherited condition) may result in accumulated plasma carnosine at supplement doses.
- · Theoretical interactions with anti-diabetic pharmaceuticals owing to the metabolic effects.
- · No documented long-term safety concerns at typical supplement doses.
Contraindications
- · Not authorised as a medicine for cognitive indications in the UK.
- · Pregnancy and lactation at supplement doses — consult healthcare provider.
- · Known hypersensitivity to peptide components.
Section 8
UK & EU Regulatory Context
United Kingdom
Available as a dietary supplement in the UK. Not a licensed medicine for cognitive or clinical indications.
European Union
Available as a dietary supplement across the EU. Not approved as a medicinal product for cognitive indications.
Section 9
Clinical Studies Summary
Carnosine antioxidant and anti-glycation characterisation
Foundational characterisation of carnosine's antioxidant and anti-glycation mechanisms, establishing the mechanism-of-action framework that underlies the compound's cognitive-relevance research applications and providing the biochemical scaffold for the diabetes-associated cognitive dysfunction and age-related protein-modification research angles.
Carnosine in Alzheimer's disease model systems
Preclinical characterisation of carnosine's effects in Alzheimer's disease model systems, reporting anti-amyloid effects via metal-chelation and direct amyloid-beta binding, plus antioxidant protection against amyloid-mediated oxidative damage. Provides the mechanism-of-action scaffold for the cognitive-relevance research applications in AD-relevant contexts.
Carnosine in cognitive-ageing research
Research applications of carnosine supplementation in aged rodent cognitive-decline models, reporting improvements in cognitive-endpoint measures and reduced markers of age-related protein modification. Provides behavioural-level evidence for the cognitive-relevance research applications alongside the biochemistry-level mechanism characterisation.
Carnosine in diabetes-associated cognitive dysfunction
Research applications of carnosine in diabetes-associated cognitive dysfunction research contexts, exploiting the anti-glycation mechanism relevant to advanced glycation end-product (AGE) formation in diabetic contexts. Reports reduced AGE accumulation and improved cognitive endpoints in diabetic animal models.
Section 10
Frequently Asked Questions
Section 10a
Practical Research Guidance
Cycle guidance
Reconstitution & storage
UK sourcing notes
Section 11
Sourcing for Laboratory Research
Sourcing Carnosine for laboratory research
Researchers in the United Kingdom and elsewhere typically obtain Carnosine from specialist research-chemical suppliers. Purity, third-party testing, and supplier transparency are the principal differentiators worth evaluating before placing an order. The two suppliers below are commonly referenced in UK research contexts.
Reminder: research peptides are sold strictly for in vitro and preclinical laboratory purposes. Importation or supply for human consumption is not permitted under UK medicines legislation.